Development of rapid multistep carbon-11 radiosynthesis of the myeloperoxidase inhibitor AZD3241 to assess brain exposure by PET microdosing.
Nuclear medicine and biology June 2015 Peter Johnström, Linda Bergman, Katarina Varnäs et al.
The myeloperoxidase inhibitor AZD3241 has been selected as a candidate drug currently being developed to delay progression in patients with neurodegenerative brain disorders. Part of the decision tree for translation of AZD3241 into clinical studies included the need for assessment of brain exposure in non-human primates by PET microdosing. For that purpose a rapid multistep method for...
DOI: 10.1016/j.nucmedbio.2015.02.001 (opens in new tab)
Full text (opens in new tab)
Microdosing
Azd3241
Carbon-11
Cyanation
+2